nextconsensus.com valid
NextConsensus
NextConsensus estimates the probability that guideline bodies, regulators, and payers will act on changing medical evidence before your review deadline.
- Authority
- 48 reach 0 · trust 8 · quality 25 · freshness 15
- Tier
- listed
- llms.txt
- https://nextconsensus.com/llms.txt
- llms-full.txt
- https://nextconsensus.com/llms-full.txt
- Sections
- 7
- Links
- 65
- Size
- 28255 bytes
- Registered
- 2025-02-19
- Country
- — Publisher location unknown; CDN address excluded
- Country evidence
- No published address evidence collected yet
- For agents
- Documentation: developer or product docs worth reading, nothing to call
- First seen
- 2026-10-26T16:57:39.805Z
- Last checked
- 2026-10-26T16:57:41.204Z
- Badge
Their llms.txt
The beginning of the file, from our validated copy saved 2026-10-26T16:57:39.810Z. Cached copy · Source on nextconsensus.com
# NextConsensus
> NextConsensus estimates the probability that guideline bodies, regulators, and payers will act on changing medical evidence before your review deadline.
NextConsensus provides dated evidence histories and registered forecasts for defined guideline, label, and coverage decisions.
Each entry below is a page's own title and description, listed in the order of the sitemap. Full page text: https://nextconsensus.com/llms-full.txt
## Registered forecasts
- [Registered forecasts](https://nextconsensus.com/forecast/): Probabilities for FDA approvals by PDUFA date, NICE guidance by scheduled date, and NCCN listings, registered before the outcome under a rule that settles each.
- [PDUFA calendar 2026–2027: FDA goal dates with registered forecasts](https://nextconsensus.com/pdufa-calendar/): FDA PDUFA goal dates for 27 applications, by month: the drug, the applicant, the review center, and a probability of approval registered before each date.
- [NICE appraisal calendar 2026–2027: expected dates with registered forecasts](https://nextconsensus.com/nice-appraisal-calendar/): Expected NICE publication dates for 23 technology appraisals, by month: NICE's title, project ID and committee, and a probability registered before each date.
- [75% forecast: NCCN lists sunvozertinib as a first-line option in EGFR exon 20 insertion NSCLC](https://nextconsensus.com/forecast/ff-001/): Registered 2026-08-17, before the outcome was known, at 75%, against a base rate of 62%. The rule that settles it is public; event by 2027-07-31.
- [88% forecast: FDA approves a first-line indication for sunvozertinib in EGFR exon 20 insertion NSCLC](https://nextconsensus.com/forecast/ff-002/): Registered 2026-09-22, before the outcome was known, at 88%, against a base rate of 85%. The rule that settles it is public; event by 2027-07-31.
- [55% forecast: FDA approves first-line sunvozertinib in EGFR exon 20 insertion NSCLC on or before 2027-03-31](https://nextconsensus.com/forecast/ff-003/): Registered 2026-09-22, before the outcome was known, at 55%, against a base rate of 60%. The rule that settles it is public; event by 2027-03-31.
- [45% forecast: FDA first-line approval of sunvozertinib precedes the NCCN first-line listing](https://nextconsensus.com/forecast/ff-004/): Registered 2026-09-22, before the outcome was known, at 45%, against a base rate of 50%. The rule that settles it is public; event by 2027-07-31.
- [82% forecast: FDA approves the aficamten MAPLE-HCM supplement to NDA 219083 on or before the disclosed PDUFA goal date of 2026-11-14](https://nextconsensus.com/forecast/ff-005/): Registered 2026-09-26, before the outcome was known, at 82%, against a base rate of 85%. The rule that settles it is public; event by 2026-11-14.
- [85% forecast: FDA approves BBP-418 for limb-girdle muscular dystrophy type 2I/R9 on or before the disclosed PDUFA goal date of 2026-11-27](https://nextconsensus.com/forecast/ff-006/): Registered 2026-09-26, before the outcome was kno
…Related sites
Similar publisher descriptions and documentation. Similarity does not imply affiliation or equivalent capabilities.
| Domain | Title | Category | Country | Authority | llms.txt | llms-full.txt | Save |
|---|---|---|---|---|---|---|---|
| biopharmawatch.com | BiopharmaWatch | documentation Finance and payments Data and analytics | FI | 51 | ✓ | ||
| 2minutemedicine.com | 2 Minute Medicine | transactional AI and machine learning Healthcare | US | 56 | ✓ | ||
| facetlifesciences.com | Facet Life Sciences | documentation | US | 46 | ✓ | ||
| visionlifesciences.com | Vision Lifesciences | documentation Healthcare | US | 51 | ✓ | ||
| oncozine.com | Onco'Zine: International Oncology Network \- Cancer \& Hematology News | informational Media Healthcare | US | 51 | ✓ | ||
| nicox.com | Nicox: Visible Science | documentation Marketing Healthcare | FR | 52 | ✓ | ||
| frontiermeds.com | Frontier Medicines | informational Marketing Healthcare +1 | — | 51 | ✓ | ||
| evaluate.com | Evaluate: Pharma commercial intelligence, news \& analysis | documentation Media Healthcare +1 | IE | 58 | ✓ |
Machine-readable: GET /v1/resolve?q=nextconsensus.com · GET /v1/domain/nextconsensus.com · this page as Accept: application/json or text/markdown · MCP lookup_domain
Automatically discovered from public files. Inclusion does not imply endorsement or publisher participation.
Own or manage this website?
If you own or manage nextconsensus.com, you can update its listing and review file health, discovery activity and score history.
Manage this listing — optional
What verification unlocks
See how your site is discovered—and control what agents see.
- See your website in the map
Review your indexed topics, nearby publishers sharing headings, measured listing exposure and map snapshots in a private report for your website.
- Control what agents see
Edit your listing description, tags, public contact details and additional llms.txt paths. Publish your terms for automated access, attribution and pricing.
- Make your profile eligible for search
A valid, listed, unblocked, verified profile can appear in our publisher sitemap and become eligible for search-engine visibility. Search engines decide what to index and rank.
- Appear in our llms-full.txt
Eligible verified publishers are listed by name, with their file links and summaries, in the service overview agents can read.
Free. No account registration, backlink or payment required. Public discovery remains available without verification.
Let your coding agent verify it
If your coding agent is authorized to manage this website, paste these instructions into it.
Claim my listing on Agent Web Map for nextconsensus.com:
1. POST https://agentwebmap.com/v1/sites/nextconsensus.com/claims and keep claim_id and claim_secret private.
2. Publish the verification line "AgentWebMap verification: <token>" (token from step 1) in https://nextconsensus.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes. This only verifies the listing; your website and domain remain yours.
3. POST https://agentwebmap.com/v1/sites/nextconsensus.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/nextconsensus.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verifyCorrections or removal requests: contact the directory.